Ben Fidler
Ben Fidler covers how drug development, clinical data and corporate strategy intersect, focusing on what trial readouts and regulatory decisions mean for the biopharma business. He writes for BioPharma Dive on the companies, programs and trends that move the drug industry’s commercial fortunes.
Drug development setbacks and inflection points
Fidler’s core focus is the business impact of drug development results, especially late-stage trials where the stakes are highest. He regularly reports on Phase 2 and Phase 3 studies, explaining not just whether a drug met its endpoints but what that means for a company’s pipeline and competitive position. In coverage of cancer immunotherapies, such as combinations that fail to improve outcomes in melanoma, he pulls apart the design, endpoints and benchmarks that define success or disappointment. His reporting often centers on inflection points for key programs — pivotal trials, high-profile failures, portfolio resets — and lays out how those moments reshape strategic priorities inside large pharmaceutical companies and biotech developers.
Across these stories he treats clinical data as a business event, translating hazard ratios, response rates and progression-free survival into implications for market share, future investment and partner interest. Negative or mixed results receive as much attention as clear wins, with context on sunk R&D costs, opportunity costs and how management teams respond. That makes his coverage a useful guide to which experimental drugs are emerging as future franchises and which once-promising assets are becoming write-offs.
Big pharma strategy, partnerships and the deal economy
Alongside trial coverage, Fidler spends significant time on how companies structure their portfolios and partnerships. He writes about licensing deals, research collaborations and acquisitions that reshape pipelines, detailing which assets are changing hands and why the terms matter. His articles track how big pharma turns to smaller biotechs to fill gaps in oncology, immunology and other high-value areas, and how those biotechs depend on milestone payments and co-development agreements to keep programs moving.
He also follows strategic retrenchment: companies exiting therapeutic areas, shelving once-priority projects, or reorganizing R&D around a narrower set of modalities. When a major drug stumbles, his follow-up coverage often examines how executives attempt to reframe strategy, whether by doubling down in the same category, diversifying into new mechanisms, or looking to deals to rebuild the pipeline. Financial details are used to ground these shifts — upfront payments, milestones, sales expectations — but his emphasis stays on what decisions say about longer-term direction rather than on short-term market reaction.
Regulatory outcomes and market expectations
Fidler’s reporting frequently tracks drugs through regulatory milestones, from filings and advisory committee meetings to approvals and rejections. He explains how regulators view the same data companies and investors have been debating, and what additional evidence they demand. When an approval comes with restrictive labeling, safety warnings or postmarketing requirements, his stories spell out how that shapes real-world uptake and revenue prospects. Conversely, when regulators push back, he details the remaining paths forward, such as new trials, different endpoints or narrower target populations.
Across these regulatory stories, he writes with an eye toward expectations. He highlights when approvals arrive earlier than anticipated, when advisory panels upend consensus, or when safety concerns undermine once-optimistic projections. Comparisons to rival drugs are common, positioning new therapies against established standards of care and other late-stage competitors in the same indication. The result is coverage that situates each decision within a broader landscape of therapeutic options and commercial dynamics.
Explanatory, data-grounded coverage for a business audience
Stylistically, Fidler writes in a straightforward, explanatory mode that assumes readers care about both the science and the balance sheet. His pieces typically combine concise news leads with several layers of context: how the new findings fit into prior data, what analysts and company executives are saying, and what comes next in development or commercialization. He is careful about overhyping early data, distinguishing between exploratory signals and results robust enough to underpin a filing or a major investment.
Over years on the beat, he has developed a consistent focus on the largest global drugmakers and the smaller developers tied to them through collaborations and licensing deals. His story mix spans quick-turn news on trial readouts and regulatory events, as well as deeper looks at how specific companies manage risk across broad portfolios. For anyone tracking where the next wave of cancer and other high-impact drugs will come from, and how those bets affect the business fortunes of drug makers, his byline offers steady, analytically minded coverage.
4 more business journalists.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex Smith
Alex Smith focuses on the business impact of enterprise technology, with a distinctive emphasis on AI literacy and skills rather than technical specifications. They write for Technology Record, covering how artificial intelligence and cloud platforms from major providers are turned into concrete programmes for organisations and governments. Their beat sits at the junction of business strategy, national digital policy and large-scale technology partnerships. They report on national AI literacy programmes and public–private partnerships, showing how policy choices, vendor capabilities and skills gaps intersect. On the business beat, they treat AI and cloud as tools for competitiveness, workforce readiness and participation in a data-driven economy. Their concise, announcement-led reporting highlights who is partnering with whom, what programme is being launched, which technologies underpin it and how it changes capability on the ground for executive readers.
Alison Durkee
Alison Durkee focuses on how law, regulation and politics create business risks for major companies and industries. She is a reporter at Forbes, where she writes news-driven explainers on complex legal and regulatory developments and their impact on corporate strategy, reputation and markets. Her coverage centers on companies under scrutiny, especially in technology and other high-growth sectors, and tracks trials, investigations and fast-changing policy fights. She breaks down lawsuits, inquiries and regulatory moves into clear parts, grounded in timelines, filings and official actions. She reports on generative artificial intelligence and other emerging technologies as tests of legal frameworks and corporate risk management, explaining how issues like intellectual property, safety compliance, consumer protection and governance can reshape product roadmaps, partnerships and investor expectations.
Alyson Shontell
Alyson Shontell covers business through the lens of leadership, using in-depth conversations with powerful executives and founders to show how their decisions shape companies, markets, and public life. She is editor in chief at Fortune, overseeing coverage across the masthead while continuing to write selected high-impact pieces. Her core work is long, reported interviews and profiles of CEOs of large companies, dominant tech firms, and fast-growing startups. She focuses on how leaders think, manage risk, make unconventional calls, and handle crises, culture, and the future of work. Her subjects include corporate chiefs, startup founders, and political figures treated as executives. She probes operating detail, governance, internal culture, and trade-offs around growth, disruption, and workplace models, using concrete examples and direct, accessible prose that foregrounds the subject’s voice while pressing for specifics.